Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Centogene N.V is a diagnostics & research business based in the US. Centogene N-V shares (CNTG) are listed on the NASDAQ and all prices are listed in US Dollars. Centogene N-V employs 660 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Guided investing
Our top pick for
Building a portfolio
Our top pick for
Beginners
| Latest market close | $4.52 |
|---|---|
| 52-week range | $4.33 - $14.00 |
| 50-day moving average | $7.12 |
| 200-day moving average | $9.74 |
| Wall St. target price | $11.93 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-1.60 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $4.52 from 2022-01-14
| 1 week (2022-01-10) | -6.22% |
|---|---|
| 1 month (2021-12-17) | -16.37% |
| 3 months (2021-10-15) | -53.92% |
| 6 months (2021-07-16) | -55.56% |
| 1 year (2021-01-15) | -60.87% |
|---|---|
| 2 years (2020-01-17) | -66.91% |
| 3 years (2019-01-13) | N/A |
| 5 years (2017-01-13) | N/A |
| Revenue TTM | $217.3 million |
|---|---|
| Gross profit TTM | $46.7 million |
| Return on assets TTM | -10.6% |
| Return on equity TTM | -64.47% |
| Profit margin | -14.43% |
| Book value | $1.65 |
| Market capitalisation | $113.5 million |
TTM: trailing 12 months
We're not expecting Centogene N-V to pay a dividend over the next 12 months.
Over the last 12 months, Centogene N-V's shares have ranged in value from as little as $4.33 up to $14. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Centogene N-V's is -2.0541. This would suggest that Centogene N-V's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Centogene N-V has bucked the trend.
Centogene N. V. , together with its subsidiaries, focuses on rare diseases that transforms real-world clinical and genetic, or other data into actionable information for patients, physicians, and pharmaceutical companies worldwide. The company develops rare disease platform, a data repository, which includes epidemiologic, phenotypic, and heterogenetic data that enhances methods for identifying and monitoring rare hereditary diseases and provide solutions that accelerate the development of orphan drugs. It provides various services, including target discovery, early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring; and genetic sequencing and diagnostics services to physicians, laboratories, or hospitals directly or through distributors. The company also offers COVID-19 testing solutions, including RT-PCR and antigen testing services. It has a strategic collaboration with Shire International GmbH and Pfizer Inc.
Donut earns up to 10% APY, but you must have an iOS device.
Car-sharing service Turo has filed plans for an IPO. What you need to know.
Monie offers 5% APY on deposits, but funds aren’t insured and the interface is buggy.
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.
Record vehicle deliveries cause the Tesla stock price to move close to all-time highs.
Everything we know about the Affinia Therapeutics IPO, plus information on how to buy in.
Everything we know about the Austin Gold IPO, plus information on how to buy in.
Everything we know about the VinFast IPO, plus information on how to buy in.
Creating a golf club is a thus-far unique application of NFTs, and another step forward for the decentralized economy.
Everything we know about the Nexalin Technology IPO, plus information on how to buy in.